Physician profile
Ankur Mansukhlal Manvar
NPI 1598025983
$33,362.61
in general payments reported to CMS, 2019-2025
38 companies · $6,715 in 2025
The $6,715 reported for 2025 was more than what 93% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,515 · 2020: $4,233 · 2021: $2,770 · 2022: $2,352 · 2023: $5,491 · 2024: $3,287 · 2025: $6,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $3,090 · Honoraria: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,903.35 |
| Travel and Lodging | $3,089.86 |
| Honoraria | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,894.35 | 2019-2025 | Eterna, Proclaim, Octrode |
| Boston Scientific Corporation | $4,117.62 | 2019-2025 | Wavewriter Alpha Prime 16, G4 Rf Generator |
| Nevro Corp. | $3,619.29 | 2019-2024 | Senza |
| Spr Therapeutics, INC | $3,524.55 | 2019-2025 | Sprint Pns System |
| Forte Bio-Pharma LLC | $3,377.13 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Saluda Medical Americas, INC. | $2,793.65 | 2024-2025 | Evoke |
| Si-Bone, INC. | $1,767.23 | 2021-2024 | |
| Medtronic, INC. | $1,553.39 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Accurian |
| Medtronic USA, INC. | $1,462.58 | 2019 | |
| Nalu Medical, INC. | $773.89 | 2022-2025 | Nalu Neurostimulation System |
| Avanos Medical | $491.70 | 2019-2025 | Generator |
| Scilex Pharmaceuticals INC. | $376.74 | 2020-2025 | Ztlido |
| Curonix LLC | $302.63 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Globus Medical, INC. | $266.45 | 2025 | Senza |
| Kowa Pharmaceuticals America, INC. | $255.09 | 2022-2023 | Seglentis |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $250.05 | 2023-2025 | Horizant, Horizant |
| Almatica Pharma LLC | $187.73 | 2022-2023 | Gralise |
| Stimwave Technologies Incorporated | $175.78 | 2019 | |
| Ibsa Pharma INC. | $172.82 | 2022-2025 | Tirosint, Licart, Flector |
| Pfizer INC. | $154.53 | 2019-2021 | |
| Assertio Therapeutics, INC. | $140.41 | 2019 | |
| Vertiflex, INC. | $130.45 | 2019 | |
| Vertos Medical, INC. | $120.98 | 2022-2024 | Mild Device Kit |
| Bioventus LLC | $56.76 | 2022-2025 | Gelsyn-3 |
| Vertex Pharmaceuticals Incorporated | $55.04 | 2024-2025 | |
| Abbvie INC. | $53.61 | 2022-2025 | |
| Painteq LLC | $46.68 | 2023-2024 | Painteq |
| Convatec INC. | $34.69 | 2025 | |
| International Rehabilitative Sciences, INC | $28.61 | 2023-2024 | Rs 4i Plus Sequential Stimulator |
| Fisher & Paykel Healthcare INC | $24.69 | 2025 | Fisher & Paykel Healthcare |
| Biotronik Nro, INC. | $23.67 | 2025 | Prospera |
| Atland Pharmaceuticals, LLC | $23.37 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Tonix Medicines, INC. | $20.96 | 2025 | Tonmya |
| Mindray Ds USA, INC. | $20.20 | 2022 | |
| Virtus Pharmaceuticals LLC | $18.16 | 2025 | Levorphanol Tartrate |
| Collegium Pharmaceutical, INC. | $17.08 | 2025 | Belbuca |
| Foundation Fusion Solutions, LLC | $17.03 | 2023 | |
| Medline Industries Lp | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Manvar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.